KEY POINTS
- Replimune Group shares surged 85% on 48 million shares after the company announced FDA alignment on a path to resubmit its Biologics License Application for RP1 in advanced melanoma.
- The resubmission follows an April 10 Complete Response Letter that had cratered the stock by roughly 64%, making this a dramatic reversal for shareholders who held through the rejection.
- The FDA indicated it would treat the BLA resubmission as an urgent matter and prioritize review, an unusual accommodation that signals the agency sees merit in the 34% response rate data from the IGNYTE trial.
Replimune Group soared 85% on volume of 48 million shares — more than 20 times its average daily turnover — after announcing that the FDA had aligned on a path forward for resubmission of its Biologics License Application for RP1, a next-generation oncolytic immunotherapy for advanced melanoma. The move marks one of the most dramatic reversals in biotech this year, coming less than two months after a Complete Response Letter had sent the stock into freefall.
The backstory matters. On April 10, Replimune received a CRL from the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for melanoma patients who had progressed on anti-PD-1 therapy. The rejection sent shares plunging roughly 64% and triggered class-action lawsuits from shareholders who alleged the company had not adequately disclosed regulatory risk. For a small-cap biotech that had staked its pipeline on this single asset, the CRL appeared to be an existential blow.
What Changed at the FDA
The announcement that shifted everything was deceptively simple: following collaborative communications, Replimune and the FDA agreed on a path for BLA resubmission. But the details underneath that headline are significant. The FDA indicated it would treat the resubmission as an urgent matter upon receipt and prioritize its review — language that is highly unusual and suggests the agency itself sees unmet medical need that RP1 could address.
The departure of former FDA Commissioner Marty Makary, whose tenure was marked by heightened scrutiny of accelerated approvals, appears to have opened a window. The acting leadership seems more receptive to the data Replimune has generated, particularly in a disease setting where patients who fail anti-PD-1 therapy have limited options.
The Clinical Case
The data supporting RP1 comes from the IGNYTE trial, which enrolled melanoma patients with confirmed progression on anti-PD-1-based regimens. In that population, RP1 plus nivolumab demonstrated a 34% overall response rate with a median duration of response of 24.8 months. For patients who have already failed the standard-of-care checkpoint inhibitor, a 34% response rate with durable responses exceeding two years is clinically meaningful — these are patients with few alternatives.
The safety profile was favorable, with the oncolytic virus mechanism producing mostly injection-site reactions and flu-like symptoms rather than the severe immune-related adverse events common with systemic immunotherapy combinations. For oncologists treating refractory melanoma, RP1 represents a genuinely differentiated mechanism of action.
Trading the Binary
For traders, Replimune is now a binary event stock with a clearer timeline than it had before the CRL. The company plans to resubmit the BLA imminently, and the FDA's commitment to prioritized review suggests a PDUFA date could come as early as Q4 2026 or Q1 2027. That creates a defined catalyst window, which biotech event traders prize.
The risk is equally defined. A second rejection would almost certainly be fatal for the stock at its current market cap. The company's pipeline beyond RP1 is early-stage, and the legal overhang from shareholder lawsuits filed after the April CRL adds a layer of uncertainty. But for traders who specialize in FDA binary events, the setup — a prioritized review of a drug with strong efficacy data in an underserved indication — is among the more attractive risk-reward profiles in small-cap biotech right now.
What Comes Next
The immediate catalyst is the formal resubmission filing and the FDA's acceptance of that filing, which will start the review clock and establish a PDUFA target date. Beyond that, investors will watch for any additional IGNYTE data readouts and the company's cash position — Replimune needs to fund operations through a potential approval and commercial launch without dilutive financing. The stock's next major move hinges entirely on the FDA's response to the resubmission. Until that clarity arrives, REPL will trade as one of the highest-volatility names in the biotech universe.
